News Summary

Elon Musk’s brain-implant company, Neuralink, is set to begin a clinical trial in October that aims to assist individuals with speech impairments by translating their thoughts into text. This trial, conducted through an FDA investigational device exemption, seeks to help people communicate by using their minds to control computers, including virtual keyboards. By directly translating thoughts from the speech cortex, the process can be significantly expedited. Neuralink, which already has several trials in the US, Canada, the UK, and the UAE, hopes this technology will eventually allow individuals to interact with AI models at the speed of thought, potentially offering life-changing improvements for those with severe impairments.